Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
Andrew H. Wei, Hartmut Döhner, Christopher Pocock, et al.
New England Journal of Medicine (2020) Vol. 383, Iss. 26, pp. 2526-2537
Open Access | Times Cited: 336

Showing 1-25 of 336 citing articles:

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
Hartmut Döhner, Andrew H. Wei, Frederick R. Appelbaum, et al.
Blood (2022) Vol. 140, Iss. 12, pp. 1345-1377
Open Access | Times Cited: 1805
Acute myeloid leukemia: current progress and future directions
Hagop M. Kantarjian, Tapan M. Kadia, Courtney D. DiNardo, et al.
Blood Cancer Journal (2021) Vol. 11, Iss. 2
Open Access | Times Cited: 546
Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management
Shai Shimony, Maximilian Stahl, Richard M. Stone
American Journal of Hematology (2023) Vol. 98, Iss. 3, pp. 502-526
Open Access | Times Cited: 236
Towards precision medicine for AML
Hartmut Döhner, Andrew H. Wei, Bob Löwenberg
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 9, pp. 577-590
Closed Access | Times Cited: 212
Acute myeloid leukaemia
Courtney D. DiNardo, Harry P. Erba, Sylvie D. Freeman, et al.
The Lancet (2023) Vol. 401, Iss. 10393, pp. 2073-2086
Open Access | Times Cited: 191
De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017
Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, et al.
Cancer (2021) Vol. 127, Iss. 12, pp. 2049-2061
Open Access | Times Cited: 181
Cancer epigenetics in clinical practice
Verónica Dávalos, Manel Esteller
CA A Cancer Journal for Clinicians (2022) Vol. 73, Iss. 4, pp. 376-424
Open Access | Times Cited: 158
Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies
Julia Stomper, John Charles Rotondo, Gabriele Greve, et al.
Leukemia (2021) Vol. 35, Iss. 7, pp. 1873-1889
Open Access | Times Cited: 154
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach
Hagop M. Kantarjian, Tapan M. Kadia, Courtney D. DiNardo, et al.
Cancer (2021) Vol. 127, Iss. 8, pp. 1186-1207
Open Access | Times Cited: 129
Updates on targeted therapies for acute myeloid leukaemia
Sabine Käyser, Mark J. Levis
British Journal of Haematology (2021) Vol. 196, Iss. 2, pp. 316-328
Open Access | Times Cited: 127
Recent advances in targeted therapies in acute myeloid leukemia
Rahul S. Bhansali, Keith W. Pratz, Catherine Lai
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 123
Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy
Huailiang Wu, Yue Gong, Peng Ji, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 111
Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management
Guillermo Garcia‐Manero
American Journal of Hematology (2023) Vol. 98, Iss. 8, pp. 1307-1325
Open Access | Times Cited: 98
Small molecule inhibitors targeting the cancers
Guihong Liu, Tao Chen, Xin Zhang, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 91
Epigenetics-targeted drugs: current paradigms and future challenges
Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 28
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations
Nigel H. Russell, Charlotte S. Wilhelm-Benartzi, Jad Othman, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 10, pp. 1158-1168
Open Access | Times Cited: 19
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management
Shai Shimony, Maximilian Stahl, Richard M. Stone
American Journal of Hematology (2025)
Open Access | Times Cited: 3
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial
Richard A. Larson, Sumithra J. Mandrekar, Lucas J. Huebner, et al.
Leukemia (2021) Vol. 35, Iss. 9, pp. 2539-2551
Open Access | Times Cited: 70
Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations
Roland B. Walter, Yishai Ofran, Agnieszka Wierzbowska, et al.
Leukemia (2021) Vol. 35, Iss. 6, pp. 1529-1538
Closed Access | Times Cited: 70
Management of Acute Myeloid Leukemia: A Review for General Practitioners in Oncology
Ryan J. Stubbins, Annabel Francis, Florian Kuchenbauer, et al.
Current Oncology (2022) Vol. 29, Iss. 9, pp. 6245-6259
Open Access | Times Cited: 66
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status
Gail J. Roboz, Farhad Ravandi, Andrew H. Wei, et al.
Blood (2022) Vol. 139, Iss. 14, pp. 2145-2155
Open Access | Times Cited: 53
Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association
Jannik Stemler, Nick de Jonge, Nicole Skoetz, et al.
The Lancet Haematology (2022) Vol. 9, Iss. 5, pp. e361-e373
Closed Access | Times Cited: 46
Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Yasmin Abaza, Amer M. Zeidan
Cells (2022) Vol. 11, Iss. 14, pp. 2249-2249
Open Access | Times Cited: 44
Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study
Guillermo Garcia‐Manero, James McCloskey, Elizabeth A. Griffiths, et al.
The Lancet Haematology (2023) Vol. 11, Iss. 1, pp. e15-e26
Closed Access | Times Cited: 35
A Bimetallic Metal–Organic‐Framework‐Based Biomimetic Nanoplatform Enhances Anti‐Leukemia Immunity via Synchronizing DNA Demethylation and RNA Hypermethylation
Yue Song, Lingxiao Zhang, Yiqiao Wang, et al.
Advanced Materials (2023) Vol. 35, Iss. 16
Closed Access | Times Cited: 30
Page 1 - Next Page

Scroll to top